Melexopoulou Christina, Filiopoulos Vassilis, Marinaki Smaragdi
Department of Nephrology & Renal Transplantation, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Department of Nephrology & Renal Transplantation, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Transfus Apher Sci. 2024 Feb;63(1):103844. doi: 10.1016/j.transci.2023.103844. Epub 2023 Nov 3.
Therapeutic apheresis (TA) plays a significant role in various aspects of renal transplantation. It has been a necessary preconditioning component in ABO incompatible kidney transplants and an important modality in the removal of anti-human leukocyte antigen (HLA) antibodies both in the context of desensitization protocols that have been developed to allow highly sensitized kidney transplant candidates to be successfully transplanted and as treatment of antibody mediated rejection episodes post transplantation. In addition, TA has been used with various results for the management of recurrent focal segmental glomerulosclerosis. The purpose of this review is to examine the evidence supporting the application of TA as an adjunctive therapeutic option to immunosuppressive agents in protocols both before and after kidney transplantation.
治疗性血液成分单采术(TA)在肾移植的各个方面都发挥着重要作用。它一直是ABO血型不相容肾移植中必要的预处理组成部分,并且在已开发的脱敏方案中,无论是使高度致敏的肾移植候选者能够成功接受移植,还是作为移植后抗体介导排斥反应发作的治疗方法,都是去除抗人白细胞抗原(HLA)抗体的重要方式。此外,TA已用于治疗复发性局灶节段性肾小球硬化,取得了不同的结果。本综述的目的是研究支持在肾移植前后的方案中应用TA作为免疫抑制剂辅助治疗选择的证据。